drugset
drugset / Trial / NCT04714060

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

NCT04714060 ↗

Phase 2 Unknown 44 enrolled UBP Greater China (Shanghai) Co., Ltd
RandomizedCrossoverSingle-blindTreatment

Summary

A randomized, single-blind, dose-selected phase II trial to evaluate the safety, efficacy and PK of UB-621 in adults with recurrent genital HSV-2 infection

Timeline

Start
2023-10-01
Primary completion
2024-10-01
Completion
2025-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject UB-621 Monoclonal antibody 2.5 mg/kg Subcutaneous
Subject UB-621 Monoclonal antibody 5 mg/kg Subcutaneous

Indications

genital herpes